|
Apr 9
|
Market Sentiment Around Loss-Making Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
|
|
Apr 8
|
Iovance (IOVA) Stock Surges More Than 60% YTD: Here's Why
|
|
Apr 5
|
Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics
|
|
Mar 29
|
Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?
|
|
Mar 26
|
2 Soaring Growth Stocks That Could Climb Another 47% to 73%, According to Wall Street
|
|
Mar 23
|
U.S.-China Decoupling Poses Supply-Chain Risks for Drug Companies
|
|
Mar 19
|
Iovance Biotherapeutics (NASDAQ:IOVA) shareholders are still up 122% over 1 year despite pulling back 7.1% in the past week
|
|
Mar 18
|
Forget Eli Lilly. Buy This Magnificent Biotech Stock Instead
|
|
Mar 15
|
Billionaire Paul Tudor Jones and Insiders Love These 10 Stocks
|
|
Mar 7
|
1 Wall Street Analyst Thinks Iovance Biotherapeutics Stock Is Going to $32. Is It a Buy Around $17?
|
|
Mar 6
|
Iovance Biotherapeutics Stock Has 22% Upside, According to 1 Wall Street Analyst
|
|
Mar 5
|
FDA Lifts Clinical Hold on Iovance's (IOVA) Lung Cancer Study
|
|
Mar 4
|
Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer
|
|
Feb 27
|
Why Iovance (IOVA) Might Surprise This Earnings Season
|
|
Feb 26
|
1 Soaring Growth Stock That Could Rise Another 53%, According to Wall Street
|
|
Feb 25
|
Insiders Pour Millions Into These 2 Buy-Rated Stocks; Here’s Why You Might Want to Follow Their Lead
|
|
Feb 25
|
Is Iovance a Buy After Its First Regulatory Win?
|
|
Feb 23
|
This Biotech Stock Has 47% Upside, According to 1 Wall Street Analyst
|
|
Feb 23
|
The Zacks Analyst Blog Highlights Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron
|
|
Feb 22
|
Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024
|